Last reviewed · How we verify
Floseal
At a glance
| Generic name | Floseal |
|---|---|
| Also known as | non applicable, Hemostatic Matrix, Thrombin-gelatin matrix, Floseal hemostatic matrix |
| Sponsor | Ottawa Hospital Research Institute |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Study of Collagen-Based Thrombin Hemostat for the Control of Bleeding in Spinal Surgery (NA)
- Evaluation of Hemostatic Agents in Partial Nephrectomy (NA)
- Trial of Modifications to Radical Prostatectomy (PHASE3)
- Efficacy Study of FloSeal in Hemostasis After Laparoscopic Ovarian Cystectomy (NA)
- Hemostatic Agent Use and Intraoperative Blood Loss in Lumbar Spine Surgery
- Benefit of Hemostatic Sealant in Preservation of Ovarian Reserve (NA)
- Management of Persistent Epistaxis Using Floseal Hemostatic Matrix (NA)
- Collagen-thrombin Matrix Efficacy During Cardiac Surgery: a Prospective Randomized Controlled Trial (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Floseal CI brief — competitive landscape report
- Floseal updates RSS · CI watch RSS
- Ottawa Hospital Research Institute portfolio CI